Tg Therapeutics (TGTX) Receivables - Net (2014 - 2026)

Tg Therapeutics' Receivables - Net history runs 7 years deep, the most recent figure standing at $392.0 million for Q1 2026.

• In Q1 2026, Receivables - Net rose 2825.72% year-over-year to $392.0 million; the TTM figure through Mar 2026 stood at $392.0 million (up 2825.72% YoY), while the FY2025 annual figure was $305.6 million, up 136.58% from the prior year.
• Receivables - Net was $392.0 million for Q1 2026 at Tg Therapeutics, up from $305.6 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $392.0 million in Q1 2026 to a low of $88000.0 in Q2 2022.
• Historically, Receivables - Net has averaged $114.6 million across 5 years, with a median of $65.0 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net slumped 90.55% in 2022, then jumped 19768.18% in 2023.
• A 5-year view of Receivables - Net shows it stood at $88000.0 in 2022, then soared by 57960.23% to $51.1 million in 2023, then jumped by 152.84% to $129.2 million in 2024, then jumped by 136.58% to $305.6 million in 2025, then gained by 28.28% to $392.0 million in 2026.
• The last three Receivables - Net figures came in at $392.0 million (Q1 2026), $305.6 million (Q4 2025), and $265.4 million (Q3 2025), per Business Quant data.